Transplantation is now the main clinical option for the curative or palliative treatment of a wide range of diseases. However, the risks of complication persist: graft versus host reaction or graft rejection.
TRIDIAG is a cross-border project that aims to validate technologically and clinically two diagnostic tests based on MIC molecules. Used in routine clinical practice, these tests are intended to lower the incidence of graft versus graft rejection and thus reduce the burden of these very serious events in humans.
Carried by the research laboratory of Seiamak Bahram (University of Strasbourg), in partnership with the team of Robert Zeiser (University Hospital Freiburg), the team of Caner Süsal (University Hospital Heidelberg), the team of Hansjörg Schild (University Hospital Mainz) and the team of Claudia Lengerke (University Hospital Basel), this three-year project started in September 2016.
The five partners are complementary and each bring their expertise, tools and infrastructures to the success of the project. The interaction of the five teams promotes technology transfer between France, Germany and Switzerland. This synergy enables the improvement of knowledge through cutting-edge research and the more efficient development of innovative diagnostic products in the field of transplantation.